LOS ANGELES, CA / ACCESSWIRE / March 11, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (SGEN) concerning possible violations of federal securities laws. Investors, who purchased or otherwise acquired Seattle Genetics shares between October 27, 2016 and December 23, 2016, inclusive (the "Class Period"), are encouraged to contact the firm prior to the March 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at firstname.lastname@example.org.
No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the Complaint, the Company announced that the U.S. Food and Drug Administration had enforced a clinical hold or partial clinical hold on initial stage trials of the Company's experimental cancer drug, vadastuximab talirine, to assess any possible risk of hepatotoxicity. The Company mentioned that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died.
When this news was released to the public, the value of Seattle Genetics dropped, causing investors serious harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Lundin Law PC
Brian Lundin, Esq.
SOURCE: Lundin Law PC